Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 study
Giuseppe Saglio(University of Turin), Hervé Dombret(University of London Institute in Paris), M. Brigid Bradley‐Garelik(Bristol-Myers Squibb (United States)), Yeow Tee Goh(Singapore General Hospital), Andreas Hochhaus(Jena University Hospital), Philipp Erben(Heidelberg University), Frédéric Maloisel(European Union), Chao Zhu(Bristol-Myers Squibb (Germany)), Ricardo Pasqüini(Hospital de Clínicas Universidade Federal do Paraná), Tamás Masszi, Ronald Paquette, Jörge E. Cortes(Augusta University Health)
Cited by 125
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k